209 related articles for article (PubMed ID: 30214188)
21. Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMA.
Vos W; Hajian B; De Backer J; Van Holsbeke C; Vinchurkar S; Claes R; Hufkens A; Parizel PM; Bedert L; De Backer W
Int J Chron Obstruct Pulmon Dis; 2016; 11():263-71. PubMed ID: 26917956
[TBL] [Abstract][Full Text] [Related]
22. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
Moodley T; Wilson SM; Joshi T; Rider CF; Sharma P; Yan D; Newton R; Giembycz MA
Mol Pharmacol; 2013 Apr; 83(4):894-906. PubMed ID: 23389862
[TBL] [Abstract][Full Text] [Related]
23. The use of roflumilast in COPD: a primary care perspective.
Price D; Chisholm A; Ryan D; Crockett A; Jones R
Prim Care Respir J; 2010 Dec; 19(4):342-51. PubMed ID: 21085915
[TBL] [Abstract][Full Text] [Related]
24. [Clinical profile of roflumilast].
Izquierdo Alonso JL
Arch Bronconeumol; 2010 Dec; 46 Suppl 10():25-32. PubMed ID: 21316553
[TBL] [Abstract][Full Text] [Related]
25. Mucociliary Clearance in Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis and the Effect of Roflumilast.
Laube BL; Carson KA; Sharpless G; Paulin LM; Hansel NN
J Aerosol Med Pulm Drug Deliv; 2019 Aug; 32(4):189-199. PubMed ID: 30964381
[No Abstract] [Full Text] [Related]
26. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
[TBL] [Abstract][Full Text] [Related]
27. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history.
Bateman ED; Rabe KF; Calverley PM; Goehring UM; Brose M; Bredenbröker D; Fabbri LM
Eur Respir J; 2011 Sep; 38(3):553-60. PubMed ID: 21737553
[TBL] [Abstract][Full Text] [Related]
28. Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.
Porpodis K; Domvri K; Zarogoulidis P; Petridis D; Tsirgogianni K; Papaioannou A; Hatzizisi O; Kioumis I; Liaka A; Kikidaki V; Lampaki S; Organtzis J; Zarogoulidis K
Int J Chron Obstruct Pulmon Dis; 2015; 10():1123-8. PubMed ID: 26109853
[TBL] [Abstract][Full Text] [Related]
29. Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
Reid DJ; Pham NT
Ann Pharmacother; 2012 Apr; 46(4):521-9. PubMed ID: 22433610
[TBL] [Abstract][Full Text] [Related]
30. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
Oba Y; Keeney E; Ghatehorde N; Dias S
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
[TBL] [Abstract][Full Text] [Related]
31. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
[TBL] [Abstract][Full Text] [Related]
32. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis.
Luo J; Wang K; Liu D; Liang BM; Liu CT
Respir Res; 2016 Feb; 17():18. PubMed ID: 26887407
[TBL] [Abstract][Full Text] [Related]
33. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Rabe KF; Watz H; Baraldo S; Pedersen F; Biondini D; Bagul N; Hanauer G; Göhring UM; Purkayastha D; Román J; Alagappan VKT; Saetta M
Lancet Respir Med; 2018 Nov; 6(11):827-836. PubMed ID: 30224319
[TBL] [Abstract][Full Text] [Related]
34. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study.
Rogliani P; Ora J; Puxeddu E; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2018 Apr; 49():20-26. PubMed ID: 29294360
[TBL] [Abstract][Full Text] [Related]
35. Clinical Considerations for Roflumilast: A New Treatment for COPD.
Kelly Freeman ML
Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
[TBL] [Abstract][Full Text] [Related]
36. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of roflumilast in the COPD frequent exacerbator phenotype.
Wedzicha JA; Rabe KF; Martinez FJ; Bredenbröker D; Brose M; Goehring UM; Calverley PMA
Chest; 2013 May; 143(5):1302-1311. PubMed ID: 23117188
[TBL] [Abstract][Full Text] [Related]
38. Roflumilast in the management of chronic obstructive pulmonary disease.
Lipari M; Benipal H; Kale-Pradhan P
Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
[TBL] [Abstract][Full Text] [Related]
39. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
Giembycz MA; Field SK
Drug Des Devel Ther; 2010 Jul; 4():147-58. PubMed ID: 20689641
[TBL] [Abstract][Full Text] [Related]
40. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]